In phase Ib and II clinical trials (NCT01864655, N = 24, 4 w & NCT02167256, N = 159, 52 w) saracatinib was found to be reasonably safe and well tolerated in participants with mild AD, but neither showed any statistically significant treatment differences for change in either CSF total tau or p-tau, nor impact on any other primary or secondary outcomes (cognition, brain glucose metabolism) over the course of treatment [203, 204]. This evidence concerns the gene MAPT and Alzheimer disease.